Utility of Procalcitonin as a Biomarker for Sepsis in Children

J Clin Microbiol. 2020 Jun 24;58(7):e01851-19. doi: 10.1128/JCM.01851-19. Print 2020 Jun 24.

Abstract

Sepsis is a complex process defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is associated with significant morbidity and mortality rates in both adults and children, and emphasis has been placed on its early recognition and prompt provision of antimicrobials. Owing to limitations of current diagnostic tests (i.e., poor sensitivity and delayed results), significant research has been conducted to identify sepsis biomarkers. Ideally, a biomarker could reliably and rapidly distinguish bacterial infection from other, noninfectious causes of systemic inflammatory illness. In doing so, a sepsis biomarker could be used for earlier identification of sepsis, risk stratification/prognostication, and/or guidance of antibiotic decision-making. In this minireview, we review one of the most common clinically used sepsis biomarkers, procalcitonin, and its roles in sepsis management in these three areas. We highlight key findings in the adult literature but focus the bulk of this review on pediatric sepsis. The challenges and limitations of procalcitonin measurement in sepsis are also discussed.

Keywords: adults; biomarkers; pediatrics; procalcitonin; sepsis.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Infections* / drug therapy
  • Biomarkers
  • Child
  • Humans
  • Procalcitonin
  • Sepsis* / diagnosis
  • Sepsis* / drug therapy

Substances

  • Anti-Bacterial Agents
  • Biomarkers
  • Procalcitonin